Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects

BACKGROUND: Esomeprazole, a proton pump inhibitor (PPI), is widely used to treat acid-related disorders, but it has short plasma half-life which can cause insufficient gastric acid suppression, such as nocturnal acid breakthrough. A new dual delayed-release (DR) formulation of esomeprazole (Esomezol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Chul, Yang, Eunsol, Ban, Mu Seong, Kim, Yu Kyong, Hong, Sung Hee, Jung, Jina, Jang, In-Jin, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106809/
https://www.ncbi.nlm.nih.gov/pubmed/37077412
http://dx.doi.org/10.2147/DDDT.S392533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106809/
https://www.ncbi.nlm.nih.gov/pubmed/37077412
http://dx.doi.org/10.2147/DDDT.S392533

Ejemplares similares